Sartans - is their popularity justify? Review article
Article Sidebar
Main Article Content
Abstract
Angiotensin II receptor antagonists (ARB), also known as sartans, are a group of pharmaceuticals which constantly gain popularity. ARB are primarily used for the treatment of hypertension where the patient is intolerant of ACE inhibitor therapy, but more recently, they have been used for the treatment of heart failure, diabetes mellitus and nephropathy.
Main mechanism of action of sartans is to block the activation of angiotensin II AT1 receptors. Blockade of AT1 receptors directly causes vasodilation, reduces secretion of vasopressin, reduces production and secretion of aldosterone. The combined effect reduces blood pressure.
The advantages of sartans include good efficacy with once-daily dosing. What is especially important, sartans are usually well-tolerated and a safety and tolerability profile that is generally comparable to that of placebo.
In 2011 Angiotensin-II receptor antagonists are recommended as first-line therapy for hypertension. Sartans can be used in monotheraphy and as a part of combination treatment.
Recently, some studies suggest that ARB can increase the risk of myocardial infarction and increase risk of new cancer diagnosis – that problems are also discussed in this paper.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Januszewicz A., Januszewicz W., Rużyłło W.: Antagoniści receptora angiotensyny II w leczeniu chorób układu sercowo-naczyniowego. Medycyna Praktyczna, Kraków 2006.
3. Januszewicz A., Januszewicz W., Szczepańska-Sadowska E., Sznajderman M.: Nadciśnienie tętnicze. Medycyna Praktyczna 2004.
4. Darimont C., Vassaux G., Gaillard D., Ailhaud G., Négrel R.: In situ microdialysis of prostaglandins in adipose tissue: stimulation of prostacyclin release by angiotensin II. Int. J. Obes. Relat. Metab. Disord. 1994 Dec, 18(12): 783-8.
5. Cassis L.A., English V.L., Bharadwaj K., Boustany C.M.: Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004, 145: 169-174.
6. Biollaz J., Brunner H.R., Gavras I., Waeber B., Gavras H.: Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J. Cardiovasc. Pharmacol. 1982, 4(6): 966-72.
7. Fogari R., Mugellini A., Zoppi A., Marasi G., Pasotti C., Poletti L., Rinaldi A., Preti P.: Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur. J. Clin. Pharmacol. 2004 Feb, 59(12): 863-8.
8. Hegner G., Faust G., Freytag F., Meilenbrock S., Sullivan J., Bodin F.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur. J. Clin. Pharmacol. 1997, 52(3): 173-7.
9. Corea L., Cardoni O., Fogari R., Innocenti P., Porcellati C., Provvidenza M., Meilenbrock S., Sullivan J., Bodin F.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin. Pharmacol. Ther. 1996 Sep, 60(3): 341-66.
10. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., Schmieder R.E.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 2003 Jul, 115(1): 41-6.
11. Europejskie zalecenia dotyczące leczenia nadciśnienia tętniczego: stanowisko Europejskiego Towarzystwa Nadciśnienia Tętniczego 2009. Nadciśnienie Tętnicze 2010, 14(1).
12. Szczepaniak-Chcheł L., Tykarski A.: Losartan+hydrochlorotiazyd. Biblioteka Czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009.
13. Allemann Y., Fraile B., Lambert M.: Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. Journal of Clinical Hypertension 2008, 10(3): 185-194.
14. White W.B., Calhoun D.A., Samuel R.: Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial. Clin. Hypertens. 2008 Jun, 10(6): 450-8.
15. Julius S., Kjeldsen S.E., Weber M.; VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 Jun 19, 363(9426): 2022-31.
16. Nelson S.A., Dresser G.K., Vandervoort M.K.: Barriers to blood pressure control: a STITCH substudy. J. Clin. Hypertens. (Greenwich) 2011 Feb, 13(2): 73-80.
17. Hsueh W., Davidai G., Henry R.: Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension. J. Clin. Hypertens. (Greenwich) 2010 Sep, 12(9): 746-52.
18. Ernsberger P., Koletsky R.J.: Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr. Opin. Pharmacol. 2007 Apr, 7(2): 140-5.
19. Top C., Cingözbay B.Y., Terekeci H.: The effects of valsartan on insulin sensitivity in patients with primary hypertension. J. Int. Med. Res. 2002 Jan-Feb, 30(1): 15-20.
20. Dahlof B., Devereux R.B., Kjeldsen S.E. et al.: LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention ForEndpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359: 995-1003.
21. McMurray J.J., Holman R.R., Haffner S.M. et al.: Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 2010 Apr 22, 362(16): 1477-90.
22. Ambrosioni E., Leonetti G., Pessina A.C., Rappelli A., Trimarco B., Zanchetti A.: Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the ItalianPharmacoepidemiological Survey on Antihypertensive Therapy. J. Hypertens. 2000 Nov, 18(11): 1691-9.
23. Markham A., Goa K.L.: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997 Aug, 54(2): 299-311.
24. Holwerda N.J., Fogari R., Angeli P., Porcellati C., Hereng C., Oddou-Stock P., Heath R., Bodin F.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J. Hypertens. 1996 Sep, 14(9): 1147-51.
25. Filipiak K.J., Gaciong Z., Grajek S., Narkiewicz K., Tykarski A.: Konsensus w sprawie pozycji antagonistów receptora AT1 angiotensyny i inhibitorów konwertazy angiotensyny w leczeniu nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Nadciśnienie Tętnicze 2009, 13(1).
26. Sipahi I., Debanne S.M., Rowland D.Y. et al.: Angiotensin receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010, 11: 627-636.
27. Pasternak B., Svanström H., Callréus T. et al.: Use of Angiotensin Receptor Blockers and the Risk of Cancer. Circulation [online: Apr 11, 2011].